Family Heart Foundation/X
Aug 26, 2025, 09:45
FDA Expands Repatha (Evolocumab) Approval: New Options for Adults With Uncontrolled LDL-C and HoFH
Family Heart Foundation posted on X:
”FDA expands approval of Repatha® (evolocumab) for adults at risk of CV events from uncontrolled LDL-C—even without established CVD. Now approved as monotherapy for HoFH. Important update for clinicians managing FH patients.”
Find more information here.
Stay updated with Hemostasis Today.
-
Mar 2, 2026, 08:07Michael Makris: Exploring ADAMTS13, vWF Imbalance, and Endotheliopathy in Ischemic Stroke
-
Mar 2, 2026, 07:31Thrombocytopenia in Tropical Infectious Diseases – RPTH Journal
-
Mar 1, 2026, 13:17Michael Makris։ Extraterrestrial Regolith as a Trigger of the Intrinsic Coagulation Pathway
-
Mar 1, 2026, 13:11Strategic Planning Day to Shape The Future of Thrombosis and Haemostasis – THANZ
-
Mar 1, 2026, 13:06Simon Senanu: Not Every Thrombocytopenia Is Real
-
Mar 1, 2026, 12:53Kevin Tang: Evolving Burden of CVD Across Asia and Its Broader Implications for Global Health Policy
-
Mar 1, 2026, 12:02Hassan Raza: Building Sustainable Support for People with Bleeding Disorders in Pakistan
-
Mar 1, 2026, 11:40Naradja Wissmar: Raised IL-32 as a Hint to Long-Term Immune Activation Post-COVID
-
Mar 1, 2026, 11:10Mehran Ghasemzadeh: A Novel Panel Bridging Platelet Function and Clinical Presentation in Chronic ITP